Mucosal delivery of the human immunodeficiency virus-1 Tat protein in mice elicits systemic neutralizing antibodies, cytotoxic T lymphocytes and mucosal IgA

Vaccine

Volumn 21, Issue 25-26, 2003, Pages 3972-3981

  Marinaro, Mariarosaria ^a   Riccomi, Antonella ^a   Rappuoli, Rino ^b   Pizza, Mariagrazia ^b   Fiorelli, Valeria ^a   Tripiciano, Antonella ^a   Cafaro, Aurelio ^a   Ensoli, Barbara ^a   De Magistris, Maria Teresa ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b CHIRON VACCINES   (Italy)

Author keywords

Adjuvants; HIV 1 Tat protein; Mucosal vaccines

Indexed keywords

CHOLERA TOXIN; EPITOPE; ESCHERICHIA COLI ENTEROTOXIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; LT R 72; NEUTRALIZING ANTIBODY; PROTEIN; SECRETORY IMMUNOGLOBULIN; TETANUS TOXOID; TRANSACTIVATOR PROTEIN; VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIUM MUTANT; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG ACTIVITY; EPITOPE MAPPING; ESCHERICHIA COLI; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGLOBULIN BLOOD LEVEL; INTESTINE FLUID; MOUSE; MOUSE STRAIN; MUCOSA; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; T LYMPHOCYTE; VAGINA SECRETION;

EID: 0242349115     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(03)00295-0     Document Type: Article

References (56)

1. Elson CO, Dertzbaugh MT. Mucosal adjuvants. In: Ogra PL, Mestecky J, Lamm ME, Strober W, McGhee JR, Bienenstock J. editors. Handbook of mucosal immunology. San Diego, CA: Academic Press; 1994. p. 391-401.
2. Heeney J.L., Beverley P., McMichael A.et al. Immune correlates of protection from HIV and AIDS - more answers but yet more questions. Immunol. Today. 20:1999;247-251.
3. Baba T., Liska V., Hofmann-Lehmann R.et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat. Med. 6:2000;200-206.
4. Beyrer C., Artenstein A.W., Rugpao S.et al. Epidemiologic and biologic characterization of a cohort of human immunodeficiency virus type 1 highly exposed, persistently seronegative female sex workers in northern Thailand Chiang Mai HEPS Working Group. J. Infect. Dis. 179:1999;59-67.
5. Lehner T., Wang Y., Cranage M.et al. Protective mucosal immunity elicited by targeted iliac lumph node immunization with a subunit SIV envelope and core vaccine in macaques. Nat. Med. 2:1996;767-775.
6. Marx P.A., Compans R.W., Gettie A.et al. Protection against vaginal SIV transmission with microencapsulated vaccine. Science. 260:1993;1323-1327.
7. Mascola J.R., Stiegler G., VanCott T.C.et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 6:2000;207-210.
8. Mazzoli S., Lopalco L., Salvi A.et al. Human immunodeficiency virus (HIV)-specific IgA and HIV neutralizing activity in the serum of exposed seronegative partners of HIV-seropositive persons. J. Infect. Dis. 180:1999;871-875.
9. Allen T.M., O'Connor D.H., Jing P.et al. Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature. 407:2000;386-390.
10. Brodie S.J., Lewinsohn D.A., Patterson B.K.et al. In vivo migration and function of transferred HIV-1-specific cytotoxic T cells. Nat. Med. 5:1999;34-41.
11. Cafaro A., Caputo A., Fracasso C.et al. Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine. Nat. Med. 5:1999;643-650.
12. Cafaro A., Caputo A., Maggiorella M.T.et al. SHIV89.6P pathogenicity in cynomolgus monkeys and control of viral replication and disease onset by human immunodeficiency virus type 1 Tat vaccine. J. Med. Primatol. 29:2000;193-208.
13. Ogg G.S., Gin X., Bonhoeffer S.et al. Quantitation of HIV-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science. 279:1998;2103-2106.
14. van Baalen C.A., Pontesilli O., Huisman R.C.et al. Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS. J. Gen. Virol. 78:1997;1913-1918.
15. Ensoli B., Cafaro A. Novel strategies toward the development of an effective vaccine to prevent human immunodeficiency virus infection or acquired immunodeficiency virus. AIDS Clin. Rev. 1:2000;23-61.
16. Gallo R.C. Tat as one key to HIV-induced immune pathogenesis and Tat toxoid as an important component of a vaccine. Proc. Natl. Acad. Sci. U.S.A. 96:1999;8324-8326.
17. Goldstein G. HIV-1 Tat protein as a potential AIDS vaccine. Nat. Med. 1:1996;960-964.
18. Chang H.K., Gallo R.C., Ensoli B. Regulation of cellular gene expression and function by the human immunodeficiency virus type 1 Tat protein. J. Biomed. Sci. 2:1995;189-202.
19. Chang H.C., Samaniego F., Nair B.C., Buonaguro L., Ensoli B. HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic region. AIDS. 11:1997;1421-1431.
20. Ensoli B., Barillari G., Salahuddin S.Z., Gallo R.C., Wong-Staal F. Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients. Nature. 345:1990;84-86.
21. Ensoli B., Buonaguro L., Barillari G.et al. Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation. J. Virol. 67:1993;277-287.
22. Frankel A.D., Pabo C.O. Cellular uptake of the Tat protein from human immunodeficiency virus. Cell. 55:1988;1189-1193.
23. Li C.J., Ueda Y., Shi B.et al. Tat protein induces self-perpetuating permissivity for productive HIV-1 infection. Proc. Natl. Acad. Sci. U.S.A. 94:1997;8116-8120.
24. Huang L., Bosch I., Hofmann W., Sodroski J., Pardee A.B. Tat protein induces human immunodeficiency virus type 1 (HIV-1) coreceptors and promotes infection with both macrophage-tropic and T-lymphotropic HIV-strains. J. Virol. 72:1998;8952-8960.
25. Secchiero P., Zella D., Capitani S., Gallo R.C., Zauli G. Extracellular HIV-Tat protein up-regulates the expression of surface CXC-chemokine receptor 4 in resting CD4+ T cells. J. Immunol. 162:1999;2427-2431.
26. Rubartelli A., Poggi A., Sitia R., Zocchi M.R. HIV-1 Tat: a polypeptide for all seasons. Immunol. Today. 19:1998;543-545.
27. Ensoli B., Gendelman R., Markham P.et al. Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma. Nature. 371:1994;674-680.
28. Ho W.Z., Harouse J.M., Rando R.F., Gonczol E., Srinivasan A., Plotkin S.A. Reciprocal enhancement of gene expression and viral replication between human cytomegalovirus and human immunodeficiency virus type 1. J. Gen. Virol. 71:1990;97-103.
29. Re M.C., Furlini G., Vignoli M.et al. Effect of antibody to HIV-1 Tat protein on viral replication in vitro and progression of HIV-1 disease in vivo. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 10:1995;408-416.
30. Re M.C., Vignoli M., Furlini G.et al. Antibodies against full-length Tat protein and some low-molecular-weight Tat peptides correlate with low or undetectable viral load in HIV-1 seropositive patients. J. Clin. Virol. 21:2001;81-89.
31. Reiss P., Lange J.M.A., de Ronde A.et al. Speed of progression to AIDS and degree of antibody response to accessory gene products of HIV-1. J. Med. Virol. 30:1990;163-168.
32. Rodman T.C., To S.E., Hashish H., Manchester K. Epitopes for natural antibodies of human immunodeficiency virus (HIV)-negative (normal) and HIV-positive sera are coincident with two key functional sequences of HIV Tat protein. Proc. Natl. Acad. Sci. U.S.A. 90:1993;7719-7723.
33. Zagury J.F., Sill A., Blattner W.et al. Antibodies to the HIV-1 Tat protein correlated with nonprogression to AIDS: a rationale for the use of Tat toxoid as an HIV-1 vaccine. J. Hum. Virol. 1:1998;282-292.
34. Osterhaus A.D.M.E., van Baalen C.A., Gruters R.A.et al. Vaccination with Rev and Tat against AIDS. Vaccine. 17:1999;2713-2714.
35. Pauza D.C., Trivedi P., Wallace M.et al. Vaccination with Tat toxoid attenuates disease in simian/HIV-challenged macaques. Proc. Nat. Acad. Sci. U.S.A. 97:2000;3515-3519.
36. Cafaro A., Titti F., Fracasso C.et al. Vaccination with DNA containing Tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P). Vaccine. 19:2001;2862-2877.
37. Gringeri A., Santagostino E., Muça-Perja M.et al. Safety and immunogenicity of HIV-1 Tat toxoid in immunocompromised HIV-1-infected patients. J. Hum. Virol. 1:1998;293-298.
38. Calarota S., Bratt G., Nordlund S.et al. Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet. 351:1998;1320-1325.
39. Giuliani M.M., Del Giudice G., Giannelli V.et al. Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of Escherichia coli heat-labile enterotoxin with partial knockout of ADP-ribosyltransferase activity. J. Exp. Med. 187:1998;1123-1132.
40. Felber B.K., Pavlakis G.N. A quantitative bioassay for HIV-1 based on trans-activation. Science. 239:1988;184-187.
41. Barillari G., Sgadari C., Fiorelli V.et al. The Tat protein of human immunodeficiency virus type-1 promotes vascular cell growth and locomotion by engaging the alpha5beta1 and alphavbeta3 integrins and by mobilizing sequestered basic fibroblast growth factor. Blood. 94:1999;663-672.
42. Marinaro M., Boyaka P.N., Jackson R.J.et al. Use of intranasal IL-12 to target predominantly Th1 responses to nasal and Th2 responses to oral vaccines given with cholera toxin. J. Immunol. 162:1999;114-121.
43. Marinaro M., Boyaka P.N., Finkelman F.D.et al. Oral but not parental interleukin (IL)-12 redirects T helper 2 (Th2)-type responses to an oral vaccine without altering mucosal IgA responses. J. Exp. Med. 185:1997;415-427.
44. Porgador A., Staats H.F., Faiola B., Gilboa E., Palker T.J. Intranasal immunization with CTL epitope peptides from HIV-1 or ovalbumin and the mucosal adjuvant cholera toxin induces peptide-specific CTLs and protection against tumor development in vivo. J. Immunol. 158:1997;834-841.
45. Brake D.A., Goudsmit J., Krone W.J.et al. Characterization of murine monoclonal antibodies to the Tat protein from human immunodeficiency virus type 1. J. Virol. 64:1990;962-965.
46. Caselli E., Betti M., Grossi M.P.et al. DNA immunization with HIV-1 Tat mutated in the trans-activation domain induces humoral and cellular immune responses against wild-type Tat. J. Immunol. 162:1999;5631-5638.
47. Tahtinen M., Ranki A., Valle S.L., Ovod V., Krohn K. B-cell epitopes in HIV-1 Tat and Rev proteins colocalize with T cell epitopes and with functional domains. Biomed. Pharmacother. 51:1997;480-487.
48. Goldstein G., Tribbick G., Manson K. Two B cell epitopes of HIV-1 Tat protein have limited antigenic polymorphism in geographically diverse HIV-1 strains. Vaccine. 19:2001;1738-1746.
49. Ryan E.J., McNeela E., Murphy G.A.et al. Mutants of Escherichia coli heat-labile act as effective mucosal adjuvants for nasal delivery of an acellular pertussis vaccine: differential effects of the nontoxic AB complex and enzyme activity on Th1 and Th2 cells. Infect. Immun. 67:1999;6270-6280.
50. Takahashi I., Marinaro M., Kiyono H.et al. Mechanism for mucosal immunogenicity and adjuvancy of Escherichia coli labile enterotoxin. J. Infect. Dis. 173:1996;627-635.
51. Morris C.B., Thanawastien A., Sullivan D.E., Clements J.D. Identification of a peptide capable of inducing an HIV-1 Tat-specific CTL response. Vaccine. 20:2001;12-15.
52. Kim D.T., Mitchell D.J., Brockstedt D.G.et al. Introduction of soluble proteins into the MHC class I pathway by conjugation to an HIV Tat peptide. J. Immunol. 159:1997;1666-1668.
53. Moy P., Daikh Y., Pepinsky B., Thomas D., Fawell S., Barsoum J. Tat-mediated protein delivery can facilitate MHC class I presentation of antigens. Mol. Biotechnol. 6:1996;105-113.
54. Simmons C.P., Mastroeni P., Fowler R.et al. MHC class I-restricted cytotoxic lymphocyte responses induced by enterotoxin-based mucosal adjuvants. J. Immunol. 163:1999;6502-6510.
55. Addo M.M., Altfeld M., Rosenberg E.S.et al. The HIV-1 regulatory proteins Tat and Rev are frequently targeted by cytotoxic T lymphocytes derived from HIV-1-infected individuals. Proc. Natl. Acad. Sci. U.S.A. 98:2001;1781-1786.
56. Rappuoli R., Pizza M., Douce G., Dougan G. Structure and mucosal adjuvanticity of cholera and Escherichia coli heat-labile enterotoxins. Immunol. Today. 20:1999;493-500.